U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07097207) titled 'Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma' on July 11.
Brief Summary: 1. Study Title:
A Study on the Efficacy and Safety of Autocrine p40 CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cells (CD19/CD20-CAR.p40-T) in Relapsed/Refractory B-Cell Lymphoma
2. Study Objectives:
* Primary Objective: To evaluate the safety of CD19/CD20 dual-targeting CAR.p40-T cell therapy in patients with relapsed/refractory B-cell lymphoma.
* Secondary Objective: To evaluate the efficacy of CD19/CD20 dual-targeting CAR.p40-T cell therapy in patients with relapsed/refractory B-cell lymphoma.
3. Participant Intervention:
* Part...